Eva Baxter

Herston Rd
Herston, QLD 4006, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Response to correspondence on "Long-term oncological and reproductive outcomes following treatment with the levonorgestrel intra-uterine device for endometrial hyperplasia and adenocarcinoma - results from the feMMe phase 2 randomized clinical trial" by Baxter et al.

Response to correspondence on "Long-term oncological and reproductive outcomes following treatment with the levonorgestrel intra-uterine device for endometrial hyperplasia and adenocarcinoma - results from the feMMe phase 2 randomized clinical trial" by Baxter et al.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 06, 2026

Response to correspondence on "Considerations on Interpreting Temporal Trends in a Scoping Review of Endometrial Cancer Care".

Response to correspondence on "Considerations on Interpreting Temporal Trends in a Scoping Review of Endometrial Cancer Care".

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 11, 2026

Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial.

Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 16, 2026

Long-term oncological and reproductive outcomes following treatment with the levonorgestrel intra-uterine device for endometrial hyperplasia and adenocarcinoma: results from the feMMe phase 2 randomized clinical trial.

Long-term oncological and reproductive outcomes following treatment with the levonorgestrel intra-uterine device for endometrial hyperplasia and adenocarcinoma: results from the feMMe phase 2 randomized clinical trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: January 13, 2026

Women's lived experiences of being diagnosed with early-stage endometrial cancer and making treatment decisions: A systematic review and thematic synthesis.

Women's lived experiences of being diagnosed with early-stage endometrial cancer and making treatment decisions: A systematic review and thematic synthesis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: January 06, 2026

Changes and trends in endometrial cancer patterns of care: a scoping review of the literature from 2000 to 2024.

Changes and trends in endometrial cancer patterns of care: a scoping review of the literature from 2000 to 2024.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 31, 2025

Central Pathology Review of Endometrial Hyperplasia and Adenocarcinoma Before and After Treatment With the Levonorgestrel Intrauterine Device-Results From the feMMe Phase 2 Randomized Clinical Trial.

Central Pathology Review of Endometrial Hyperplasia and Adenocarcinoma Before and After Treatment With the Levonorgestrel Intrauterine Device-Results From the feMMe Phase 2 Randomized Clinical Trial.

Journal: The American journal of surgical pathology

Published: November 25, 2025

Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644].

Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644].

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 12, 2025

Extracellular vesicles as biomarkers for endometrial cancer - A systematic review.

Extracellular vesicles as biomarkers for endometrial cancer - A systematic review.

Journal: Translational oncology

Published: December 03, 2024

Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma.

Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 04, 2024

A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020.

A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 13, 2021

Improving response to progestin treatment of low-grade endometrial cancer.

Improving response to progestin treatment of low-grade endometrial cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 16, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026